Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02542384 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating the Overall Pain Relief and Safety of Intravenous (IV) CR845 in Patients Undergoing Abdominal Surgery
A Phase 2 study, sponsored by Cara Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 451
- Enrollment target
NCT02542384: Completed Phase 2 study, sponsored by Cara Therapeutics.
NCT02542384 is a Phase 2 study that has completed, run by Cara Therapeutics. The registered enrollment target is 451 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (239% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02542384, a Phase 2 study, has completed, sponsored by Cara Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 451 participants
- Enrollment target
Study Summary
The study schedule is comprised of a 14-day Screening Period, a treatment period and an observation period. All eligible subjects will be randomized into one of 3 treatment groups (1 of 2 dose levels or matched placebo). Study drug CR845 will be administered intravenously prior to surgery, and at specific time intervals post surgery. Additional rescue pain and anti-nausea medication will be made available. Post surgical changes in pain intensity, nausea and vomiting will be assessed.
Primary Outcome
Using the Numeric Rating Scale (NRS) to quantify the difference between CR845-treated patients and placebo-treated patients.
Interventions
- DRUG Placebo IV
- DRUG CR845 IV 1 mcg/kg
- DRUG CR845 IV 0.5 mcg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 451 participants |
| Start Date | 2015-09 |
| Est. Completion | 2018-06 |
| Phase | Phase 2 |
What the finished NCT02542384 record still lists
NCT02542384 is an interventional study that assigns participants to a tested intervention. The registered 451 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (239% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo IV is the first listed.
NCT02542384 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02542384 about?
NCT02542384 is a clinical study titled "A Study Evaluating the Overall Pain Relief and Safety of Intravenous (IV) CR845 in Patients Undergoing Abdominal Surgery". The study schedule is comprised of a 14-day Screening Period, a treatment period and an observation period. All eligible subjects will be randomized into one of 3 treatment groups (1 of 2 dose levels or matched placebo). Study drug CR845 will be administered intravenously prior to surgery, and at sp...
What is the current status of trial NCT02542384?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 451 participants. The study started on 2015-09. Estimated completion is 2018-06.
What interventions are being tested in trial NCT02542384?
The interventions under investigation include: Placebo IV (DRUG), CR845 IV 1 mcg/kg (DRUG), CR845 IV 0.5 mcg/kg (DRUG).
Who is sponsoring clinical trial NCT02542384?
This trial is sponsored by Cara Therapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02542384's enrollment target sits among peer trials
451 87th of 2000 higher than 1,914 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05676255 · 452 participants · Phase 2
The Breast Cancer Survivors and Partners Online Research Together (SUPORT) Project
- NCT05703178 · 452 participants · Phase 3
Web-based Pain Coping Skills Training for Breast Cancer Survivors With AI-Associated Arthralgia
- NCT00515060 · 450 participants
Psychophysical Studies of Cancer Therapy Pain
- NCT01257269 · 450 participants
Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia